- accelerate the US roll out of the Company’s flagship nerve repair product Remplir™
- undertake clinical studies to commercialise the use of Remplir in the significant prostate cancer surgery market
- advance commercialisation of pipeline products in tendon and ligament repair
- expand capacity at Orthocell’s existing manufacturing facility
- invest in new applications and technologies in the regenerative medicine sector.
Orthocell CEO and MD, Paul Anderson, said:
“We have built significant momentum in the commercialisaiton of Remplir and the funds from the capital raising will be focused on accelerating that process. We greatly appreciate the support we have received from new and existing institutional and high net worth investors and particularly welcome our new investors from the US. We see that as a significant endorsement of our strategy and progress to date as well as the near-term revenue that can be generated from the US market.” Click to read the ASX release